



 **odontoprev**
Webcast
2Q21

New growth cycle and value innovation



Disclaimer



The information contained herein has been prepared by Odontoprev S.A. (“Odontoprev” or the “Company”) and this material does not constitute offering material in whole or part.

This material has been prepared solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities and should not be treated as giving investment advice. It is not targeted to the specific investment objectives financial situation or particular needs of any recipient. No representation or warranty either express or implied is made as to the accuracy completeness or reliability of the information contained herein. It should not be regarded by recipients as a substitute for the exercise of their own judgment. Any opinions expressed in this material are subject to change without notice and OdontoPrev is not under obligation to update or keep current the information contained herein. The Company their respective affiliates. agents. directors. partners and employees accept no liability whatsoever for any loss or damage of any kind arising out of the use of all or any part of this material.

This material is intended solely for the use of persons who are market counterparties of intermediate customers (as detailed in the FSA Rules) and is only available to such persons. The information contained herein does not apply to and should not be relied upon by private customers.

You should consult your own legal regulatory tax business. Investment. financial and accounting advisers to the extent that you deem necessary and you must make your own investment hedging or trading decision based upon your own judgment and advice from such advisers as you deem necessary and not upon any view expressed in this material.


The information contained in this presentation concerning market estimates. The Brazilian dental and healthcare industry and our participation in it as well as our position in relation to our competitors was obtained from established public sources including the ANS. the Ministry of Health (Ministério da Saúde) and other market sources. We consider these sources to be reliable but we have not independently verified the competitive position market share production and market size market growth data and other market estimates and therefore cannot provide any assurances regarding the accuracy and completeness of the information contained therein.

Medical and dental plans membership growth




Million members

Medical plans



Dental plans





JUL20-JUN21 Dental players net revenue and average ticket

R\$ million

Average Ticket (R\$ / member / month)



Source: Odontoprev and ANS
¹ APR20-MAR21



Leadership position on each and every region

Key dental players per region (thousand members)



Members Ranking Members Ranking Members Ranking Members Ranking Members Ranking Members Ranking Members Ranking

Southeast	4,334	1st	1,928	3rd	2,691	2nd	545	7th	1,624	4th	825	5th	596	6th
South	728	1st	278	3rd	75	10th	81	9th	120	4th	105	5th	16	20th
Middle-West	549	1st	182	3rd	33	11th	202	2nd	146	4th	109	6th	35	10th
North Northeast	1,915	1st	488	3rd	45	21th	1,870	2nd	258	4th	106	8th	46	20th
Total ¹	7,529	1st	2,880	2nd	2,844	3rd	2,698	4th	2,151	5th	1,145	6th	693	8th


Source: ANS May/21

1- Considers unidentified beneficiaries

Quarterly net additions




Thousand members



Net additions in the last twelve months




Thousand members



Net revenue quarterly growth




R\$ million





Revenues and average ticket per segment

JUL20-JUN21 x 2014




¹ M: million

Cost of Services: consolidated and per segment




R\$ million % of Sales





Allowance for doubtful receivables

R\$ million and % of Sales






Adjusted EBITDA: 6M21 x 6M20

R\$ million % of Sales



Quarterly financial income evolution


R\$ million





Net Cash evolution


R\$ million





Shareholder remuneration

R\$ million



*updated until 07/06/2021

Highlights in ESG



In June, Odontoprev published its Annual ESG Report, prepared based on GRI (Global Reporting Initiative) guidelines



In 2Q21, the Company obtained certificate “*Amigo do Clima*”, of which total emission since its foundation were neutralized



FTSE4Good

Odontoprev was confirmed as a FTSE4Good Index Series constituent, for the fifth consecutive year, which measures the performance of companies in ESG practices.




In July, Odontoprev was one of 11 companies recommended at the ESG

Global shareholder structure: investors from more than 30 countries



JUN21



Total Capital

531,294,792 Shares

48% Free float

256,640,273 Shares

Source: Odontoprev

¹as of Notice to the Market on Nov 03rd, 2020

 odontoprev